# Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

> **NCT02782403** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- Blast Phase Chronic Myelogenous Leukemia (CML)
- Chronic Phase Phase Chronic Myelogenous Leukemia (CML)
- Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Bosutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02782403
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-20
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies.
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782403, "Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02782403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*